Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part II
N. I. Kurysheva
Affiliations
N. I. Kurysheva
The Department of Eye Diseases at the Medical Biological University of Innovations and Continuing Education of the A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency (FMBA); Diagnostic Department of the Ophthalmological Center of FMBA of Russia, Clinical Hospital No. 86
Topical and systemic carbonic anhydrase inhibitors (CAIs) are widely used in the treatment of glaucoma for reducing intraocular pressure. This part of the review describes the characteristics of systemic CAIs, their side effects and the ways to overcome them, as well as contraindications. The use of CAIs during pregnancy is considered. Particular attention is paid to the antioxidant activity of CAIs and the promising development of hybrid forms based on the existing CAIs as a part of a multipurpose glaucoma treatment strategy.
